Domov › Mnohonásobný myelóm › North Carolina › Durham
Klinické štúdie Mnohonásobný myelóm v meste Durham, NC
37 štúdií pre Mnohonásobný myelóm hľadá účastníkov v zariadeniach v meste Durham a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Prebieha náborFáza 3
- Research Site, Chapel Hill · 10 míľ odtiaľ
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Prebieha náborFáza 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Prebieha náborFáza 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Prebieha náborFáza 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · 10 míľ odtiaľ
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Prebieha náborFáza 3
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Prebieha náborFáza 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · 10 míľ odtiaľ
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Prebieha náborFáza 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 míľ odtiaľ
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Prebieha náborFáza 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Prebieha náborFáza 2
- University of North Carolina Medical Center, Chapel Hill · 10 míľ odtiaľ
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Prebieha náborFáza 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · 10 míľ odtiaľ
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Prebieha náborFáza 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Prebieha náborFáza 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 míľ odtiaľ
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Prebieha náborFáza 1/2
- GSK Investigational Site, Chapel Hill · 10 míľ odtiaľ
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Prebieha náborFáza 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Prebieha náborFáza 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Prebieha náborFáza 3
- Research Site, Durham
- Research Site, Chapel Hill · 10 míľ odtiaľ
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Prebieha nábor
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10 míľ odtiaľ
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Prebieha náborFáza 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Prebieha náborFáza 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · 10 míľ odtiaľ
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Prebieha náborFáza 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · 10 míľ odtiaľ
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Prebieha náborFáza 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Prebieha náborFáza 1
- University of North Carolina /ID# 251203, Chapel Hill · 10 míľ odtiaľ
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Prebieha náborFáza 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 míľ odtiaľ
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Prebieha náborFáza 2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 míľ odtiaľ
Registry of Older Patients With Cancer
Prebieha náborObservačná štúdia
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 míľ odtiaľ
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Prebieha náborFáza 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Prebieha náborFáza 2
- University of North Carolina, Chapel Hill · 10 míľ odtiaľ
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Prebieha náborFáza 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 10 míľ odtiaľ
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Prebieha náborFáza 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · 10 míľ odtiaľ
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Prebieha náborFáza 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Prebieha náborFáza 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · 13 míľ odtiaľ
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Prebieha náborFáza 1
- University of North Carolina, Chapel Hill · 10 míľ odtiaľ
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Prebieha náborFáza 1
- University of North Carolina, Chapel Hill · 10 míľ odtiaľ
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Prebieha náborFáza 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 míľ odtiaľ
Registry for Adults With Plasma Cell Disorders (PCD's)
Prebieha náborObservačná štúdia
- North Carolina Cancer Hospital, Chapel Hill · 10 míľ odtiaľ
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Prebieha náborObservačná štúdia
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 míľ odtiaľ
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Prebieha náborFáza 1
- Duke University Health System (DUHS), Durham
Štúdie Mnohonásobný myelóm v iných mestách
- New York City, NY60 štúdií
- Boston, MA42 štúdií
- Atlanta, GA41 štúdií
- Houston, TX38 štúdií
- Nashville, TN32 štúdií
- Denver, CO27 štúdií
- Rochester, MN24 štúdií
- St. Louis, MO24 štúdií
- Columbus, OH24 štúdií
- Baldwin Park, CA23 štúdií
- Chicago, IL22 štúdií
- Seattle, WA22 štúdií
Iné štúdie v Durham
- Rakovina prsníka63 štúdií
- Rakovina (všetky typy)58 štúdií
- Nemalobunkový karcinóm pľúc39 štúdií
- Metastatická rakovina33 štúdií
- Akútna myeloidná leukémia33 štúdií
- Rakovina pľúc32 štúdií
- Rakovina prostaty32 štúdií
- Kolorektálny karcinóm28 štúdií
- Chronická lymfocytová leukémia27 štúdií
- Rakovina vaječníkov27 štúdií
- Srdcové zlyhanie26 štúdií
- Rakovina pankreasu24 štúdií
Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.